Alignment Healthcare, Inc. (NASDAQ: ALHC) reported that Chief Executive Officer John E. Kao completed a series of stock sales on April 10 and April 13, 2026, totaling 337,900 shares of common stock for proceeds of approximately $6.16 million. The transactions were carried out while the company’s shares traded at $20.98, a level close to the 52-week peak of $23.87 and following a 12% rise in the stock over the prior week.
The dispositions were executed at weighted average prices spanning $20.5807 to $21.3785 per share. On April 10, Kao sold 201,900 shares at a weighted average of $20.5807, with individual sale prices ranging between $20.31 and $21.30. Also on April 10, an additional block of 13,801 shares was sold at a weighted average price of $21.3785, with price ticks from $21.31 to $21.49. On April 13, Kao sold 82,299 shares at a weighted average of $20.798, in trades priced between $20.26 and $21.00.
Following these transactions, Kao’s reported holdings include indirect ownership of 1,806,641 shares through the JEK Trust, dated February 8, 2021, where he serves as trustee, as well as direct ownership of 1,784,868 shares. The insider trades were carried out under a pre-established Rule 10b5-1 trading plan that Kao adopted on November 21, 2025.
Valuation context and analyst views
InvestingPro analysis referenced by the company indicates Alignment Healthcare may be trading at a modest premium to fair value at current prices, describing the stock as slightly overvalued. Analyst price targets reported range from $18 to $30. The InvestingPro service also notes that a Pro Research Report covering ALHC and more than 1,400 other U.S. equities is available for subscribers.
Corporate transactions and recent financial performance
In separate corporate activity, an affiliate of General Atlantic, L.P. is conducting a secondary offering of 13.2 million shares of Alignment Healthcare common stock, priced at $19.46 apiece. Alignment Healthcare will not receive proceeds from that sale, which is expected to close in March 2026, with J.P. Morgan serving as underwriter.
Analyst coverage following the company’s latest quarterly report remained constructive. Raymond James reiterated a Strong Buy rating and set a $27.00 price target after the fourth-quarter results. The company reported membership growth of 25% year-over-year and revenue growth of 44.4%, both beating expectations. The reported medical benefit ratio for the period was 87.7%, and selling, general, and administrative expenses improved by 115 basis points to 9.7% of revenue.
Piper Sandler also maintained a favorable view, keeping an Overweight rating with a $30.00 price target after reviewing Alignment Healthcare’s fourth-quarter 2025 performance. According to Piper Sandler, the company’s medical benefit ratio and adjusted EBITDA exceeded expectations for the period.
What this means for investors
The CEO’s sales, executed under a pre-arranged 10b5-1 plan, add liquidity to Kao’s holdings while occurring against a backdrop of positive recent operational metrics and active analyst coverage. Concurrently, a sizeable secondary offering by an affiliate of a major private investor will add shares to the market, though Alignment Healthcare itself will not receive funds from that transaction. Market participants and holders of ALHC shares will likely monitor how the combination of insider selling activity, analyst positioning, and additional share supply influences near-term trading dynamics.